CNMV
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Madrid, April 3, 2025

In accordance with the provisions of article 226 of the Spanish Securities Markets and Investment Services Act (*Ley de los Mercados de Valores y de los Servicios de Inversión*), approved by Law 6/2023, of 17 March, and concordant provisions, is hereby reported the following:

INSIDE INFORMATION

Pharma Mar, S.A. ("PharmaMar") and Merck, a global science and technology company based in Darmstadt, Germany, have entered into an exclusive licensing agreement for the development and commercialization of Zepzelca® (lurbinectedin), a novel transcription inhibitor for the treatment of small cell lung cancer (SCLC), in Japan.

Under the terms of the agreement, PharmaMar will receive an upfront payment of €22 million. PharmaMar is entitled to tiered double digit royalties on net sales, and various clinical, regulatory, and sales based milestones totalling up to an additional €31 million.

PharmaMar will supply Merck with lurbinectedin for clinical and commercial use in Japan.

Please find attached press release that will be distribute to the media.

Press Release

PharmaMar signs a new licensing, development and commercialization agreement with Merck for lurbinectedin in Japan

• PharmaMar will receive an upfront payment of €22 million and is entitled to receive up to an additional €31 million for the achievement of various milestones.

Madrid, April 3rd, 2025.- PharmaMar (MSE:PHM) a global leader in the research, development, and commercialization of marine-derived oncology therapies, and Merck (MRK.DE), a global science and technology company based in Darmstadt, Germany, today announced an exclusive licensing agreement for the development and commercialization of Zepzelca® (lurbinectedin), a novel transcription inhibitor for the treatment of small cell lung cancer (SCLC), in Japan.

Under the terms of the agreement, PharmaMar will receive an upfront payment of €22 million. PharmaMar is entitled to tiered double digit royalties on net sales, and various clinical, regulatory, and sales based milestones totalling up to an additional €31 million.

PharmaMar will supply Merck with lurbinectedin for clinical and commercial use in Japan.

"*We are excited to partner with Merck, to advance and commercialize lurbinectedin in Japan, leveraging their proven expertise in bringing innovative therapies to market. This collaboration enables us to envision Japanese patients gaining access to this new drug which already obtained marketing authorizations in 17 territories including major countries in Asia-Pacific such as China, South Korea, Taiwan, Singapore, and Australia.*" said Luis Mora, Managing Director, PharmaMar

About PharmaMar

PharmaMar is a biopharmaceutical company focused on the research and development of new oncology treatments, whose mission is to improve the healthcare outcomes of patients afflicted by serious diseases with our innovative medicines. The Company is inspired by the sea, driven by science, and motivated by patients with serious diseases to improve their lives by delivering novel medicines to them. PharmaMar intends to continue to be the world leader in marine medicinal discovery, development and innovation.

PharmaMar has developed and now commercializes Yondelis® in Europe by itself, as well as Zepzelca® (lurbinectedin), in the US; and Aplidin® (plitidepsin), in Australia, with different partners. In addition, it has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar has other clinical-stage programs under development for several types of solid cancers: lurbinectedin, ecubectedin, PM534 and PM54. Headquartered in Madrid (Spain), PharmaMar has subsidiaries in Germany, France, Italy, Belgium, Austria, Switzerland and The United States. PharmaMar also wholly owns Sylentis, a company dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.

About Zepzelca®

Zepzelca® (lurbinectedin), also known as PM1183, is an analog of the marine compound ET-736 isolated from the sea squirt Ecteinascidia turbinata in which a hydrogen atom has been replaced by a methoxy group. It is a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent. Together with its effect on cancer cells, lurbinectedin inhibits oncogenic transcription in tumor-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumor. Transcriptional addiction is an acknowledged target in those diseases, many of them lacking other actionable targets.

Media Contact:
Lara Vadillo – Communication Director lvadillo@pharmamar.com
Miriam Collados Gordo – Corporate Communication Manager mcollados@pharmamar.com
Phone: +34 918466000

Capital Markets & Investor Relations:
José Luis Moreno– VP Capital Markets & Investor Relations
Natalia Amo – Capital Markets & Investor Relations
investorrelations@pharmamar.com
Phone: +34 914444500

Or please visit our website at **www.pharmamar.com**